Cargando…

Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase

Detalles Bibliográficos
Autores principales:	Chakraborty, S, Lin, Y-H, Leng, X, Miranda, R N, Medeiros, L J, Shpall, E, Arlinghaus, R B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789205/ https://www.ncbi.nlm.nih.gov/pubmed/24013663 http://dx.doi.org/10.1038/bcj.2013.41

Ejemplares similares

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia
por: Chakraborty, Sandip N., et al.
Publicado: (2016)

Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation()
por: Tsukamoto, Shokichi, et al.
Publicado: (2013)

Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020)

Erythroid blast crisis in chronic myelogenous leukemia: Case report and review of literature
por: Nagamos, Rochelle Nagales, et al.
Publicado: (2016)

Acute megakaryoblastic blast crisis as a presentation manifestation of chronic myelogenous leukemia
por: Bhattacharya, Jenna B, et al.
Publicado: (2017)

HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells
por: Tao, Wenjing, et al.
Publicado: (2015)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

Unusual T-Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia
por: Xu, Jie, et al.
Publicado: (2014)

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder
por: Maerki, J., et al.
Publicado: (2014)

Extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: A case report of successful diagnosis and treatment
por: ZENG, DONG-FENG, et al.
Publicado: (2015)

Heralding Extramedullary Blast Crisis: Horner's Syndrome with Brachial Plexopathy in a Patient with Chronic Myelogenous Leukemia
por: Jacob, Sajish, et al.
Publicado: (2016)

Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature
por: Martinez-Cordero, Humberto, et al.
Publicado: (2019)

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature
por: Bader, Gilbert, et al.
Publicado: (2019)

Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia
por: Boudiaf, Houda, et al.
Publicado: (2020)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

“Chronic myelogenous leukemia in primary blast crisis” rather than “de novo BCR‐ABL1‐positive acute myeloid leukemia”
por: Pastoret, Cedric, et al.
Publicado: (2017)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
por: Chen, Z, et al.
Publicado: (2016)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia
por: Rosen, David B., et al.
Publicado: (2010)

Lyn, Jak2, and Raf-1 Kinases Are Critical for the Antiapoptotic Effect of Interleukin 5, whereas only Raf-1 Kinase Is Essential for Eosinophil Activation and Degranulation
por: Pazdrak, Konrad, et al.
Publicado: (1998)

JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review
por: Ogasawara, Toshie, et al.
Publicado: (2020)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

JAK-STAT in Early Hematopoiesis and Leukemia
por: Fasouli, Eirini Sofia, et al.
Publicado: (2021)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
por: Perrotti, D, et al.
Publicado: (2006)

Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding
por: Desterke, Christophe, et al.
Publicado: (2020)

Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?
por: Gao, Jiapei, et al.
Publicado: (2023)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL
por: Li, Bin, et al.
Publicado: (2016)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation
por: Ferrao, Ryan D, et al.
Publicado: (2018)

Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
por: Hubbard, Stevan R.
Publicado: (2018)

Blast phase transformation of chronic myelogenous leukemia presenting with central nervous system manifestation
por: Chikkannaiah, Panduranga, et al.
Publicado: (2016)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

The SH2 domain and kinase activity of JAK2 target JAK2 to centrosome and regulate cell growth and centrosome amplification
por: Shahi, Aashirwad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q4ofeec8gttglrbbkfqm675kqd